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Summary In patients with clinical stage I non-seminomatous testicular cancer only limited information is
available about the administrative problems with the surveillance programme, in particular if this policy is to
be implemented in a geographically extended country with limited computerised tomography (CT) resources.
One hundred and two patients with non-seminomatous testicular cancer clinical stage I and low-risk histology
(MRC criteria, UK) were followed by the surveillance policy for at least 1 year after orchiectomy (median 47
months, range 21-81 months). Twenty-two patients (22%) relapsed after a median time of 5 months (range
2-18 months), 14 of them in the retroperitoneal space. Serum a-fetoprotein and/or human chorionic
gonadotrophin were elevated in eight of the 22 relapsing patients. The progression-free and cancer-corrected
survival rates were 78% and 99% respectively. Patient non-compliance did not represent a major problem, whereas the regular and adequate performance of necessary CT examinations yielded some administrative
difficulties. One and 3 years after orchiectomy about 50% of the relapse-free patients had no psychological
problems and were satisfied with the surveillance programme, whereas 46% reported minor and 4% major
psychological distress. Despite non-negligible administrative difficulties in geographically extended countries,
surveillance is feasible and safe in compliant patients with low-risk non-seminomatous testicular cancer stage I. The responsible cancer centre and the local hospitals should establish a high degree of cooperation and enable
adequate follow-up examinations in these patients.
During recent years clinicians have to an increasing degree
attempted to avoid significant morbidity resulting from over-
treatment in patients with low-stage non-seminomatous tes-
ticular cancer and to maintain these patients' current high
cure rate. In this context the surveillance policy (wait and
see) (Peckham et al., 1982; Hoskin et al., 1986; Pizzocaro et
al., 1986; Freedman et al., 1987; Dunphy et al., 1988;
Thompson et al., 1988; Germalluch et al., 1991; R0rth et al.,
1991; Read et al., 1992; Sturgeon et al., 1992) has been
introduced in clinical stage I as an alternative to retro-
peritoneal lymph node dissection (RLND) (Aass et al., 1990;
Weissbach et al., 1990; Klepp et al., 1991). However, the
advantages and drawbacks of the surveillance policy as com-
pared with primary RLND have remained a matter of dis-
cussion.
Each year between 80 and 90 patients with newly diag-
nosed testicular cancer are seen at the Norwegian Radium
Hospital (NRH), comprising about 50% seminoma and 50%
non-seminoma patients. Until 1987 patients with non-
seminoma clinical stage I underwent primary RLND, fol-
lowed by post-operative adjuvant chemotherapy in the case
of retroperitoneal metastases (Aass et al., 1990). In 1987 it
was decided to introduce a surveillance policy. Initially it was
feared that the Norwegian Health Care System and the
geography of the country would pose considerable difficulties
to a follow-up schedule where frequent controls at an
oncological unit are mandatory. Some of the patients seen at
the Norwegian Radium Hospital at that time had, for exam-
ple, to travel about 1,000 km in order to reach the responsi-
ble oncological centre. The median distance from the
patients' living place to the NRH was 83 km (range
0-1,200 km).
We herein review the experience with the surveillance
policy in the first 102 patients followed for at least 12 months
after orchiectomy (until 1 December, 1993), concentrating on
aspects of the feasibility and safety of this option.
Materials and methods
Patients
From March 1987 to January 1992 121 patients with newly
diagnosed clinical stage I non-seminomatous testicular cancer
were referred to the Norwegian Radium Hospital for primary
treatment.
Histopathology
Histological sections of the primary tumour from all patients
were reviewed at the Department of Pathology, NRH, ac-
cording to the Pugh classification (Collins & Pugh, 1964) and
the presence and absence of the four histological risk criteria
previously described by Freedman et al. (1987). One hundred
and three patients had low-risk and 18 patients had high-risk
histology (Freedman et al., 1987).
Radiology
After clinical examination (which in stage I patients revealed
normal findings) abdominal and thoracic computerised
tomography (CT) was performed either at the Department of
Radiology at the NRH or at the local hospital. In the latter
case the CT films were reviewed at the NRH. Early during
the period of surveillance the responsible consultants of the
radiological departments of the referring hospitals had a
consensus meeting and agreed on a technique (spacing, thick-
ness ofsections, use ofcontrast) considered to be optimal for
staging of testicular cancer patients. The presence or absence
of enlarged lymph nodes and their size and localisation
should be recorded. If present, the number oflung metastases
should be given together with the diameter of the largest
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metastasis. Based on previous experience with RLND at our
institution the radiological criterion for testicular cancer
clinical stage I was defined as absence of any visible
retroperitoneal lymph nodes or multiple lymph nodes each
< 10mm or a solitary lumph node <S15mm (Lien et al.,
1986). No metastases should be seen on the thoracic CT
scans.
Biochemistry
At the time of staging the serum levels of a-fetoprotein
(AFP) and human choriogonadotropin (HCG) had to be
normal (AFP< 15 ig 1-; HCG< 10 U l-).
Decision oftreatment policy
In one of the 103 low-risk patients primary RLND was
recommended and subsequently performed. This patient was
schizophrenic and was not regarded as suitable for a surveil-
lance programme. Each of the remaining 102 patients was
verbally and by letter introduced to the two available
options: either to undergo nerve-sparing RLND or to be
included into the surveillance policy. The risk of complica-
tions and the frequency of necessary follow-up routines were
clearly described for both treatment modalities together with
the risk of recurrence. In particular, the high frequency of
control visits was emphasised for patients considering surveil-
lance. All 102 patients opted for surveillance.
Follow-up
Clinical examination, chest radiography and serum tumour
marker determination were to be done every month during
the first year, every second month during the second year,
every third month during the third year and every sixth
month during the fourth and fifth years. According to this
schedule relapse-free patients should have had between 9 and
11 control visits during the first post-orchiectomy year depen-
ding on the time of initial staging in a particular patient.
Abdominal and thoracic CT scans were taken at 2, 4, 8 and
12 months. In the case of suspicious findings additional
examinations were performed as clinically indicated.
The first four follow-up examinations were done at the
NRH by one of two consultant oncologists dedicated to the
work with patients with testicular cancer. Thereafter, several
of the control tests, including CT scanning, could be per-
formed at the local hospital organised by an interested
urologist or oncologist who had been informed about the
importance of regular follow-up visits in these patients. Such
controls at local hospitals were preferably done in patients
who lived >200 km from the NRH.
The frequency and results of the follow-up examinations
during the first year were recorded in the patient's medical
record at NRH even though the examinations were per-
formed locally. All follow-up CT scans from local hospitals
were reviewed at the NRH. If a patient did not show up for
a planned follow-up visit, he was contacted twice reminding
him of his responsibility to adhere to the control schedule.
In order to evaluate the psychological burden the surveil-
lance programme might have posed on the patients, the first
68 recurrence-free patients completed a questionnaire at the 1
year control visit evaluating their satisfaction with the wait
and see policy and the psychological distress they had
experienced. Forty-six patients filled in the same question-
naire at the 3 year follow-up visit. The questionnaire had
previously been used at the NRH in a prospective investiga-
tion of testicular cancer patients (Aass et al., 1992).
Statistics
All data were stored in a personal computer and analysed
using the MEDLOG program (Wilcoxon rank test, medians,
ranges, chi-quare test, survival rates according to Kap-
lan-Meier with log rank estimation of differences). A P-
value <0.05 was considered to be statistically significant.
Results
The median number of follow-up visits performed during the
first year after orchiectomy was 10 (range 2-16) (Figure la).
One continuously relapse-free patient with a severe per-
sonality disorder refused further follow-up after 2 months. In
the others at least six control visits were performed. The
median number of CT scans during follow-up was 4 (range
0-7; Figure lb). Four patients had only two CT scans and
23 patients underwent only three CT examinations mainly
owing to capacity and administrative problems at the respon-
sible radiological units. If a patient met for more than 12
follow-up visits and/or more than four CT scans were done,
this was because of equivocal or suspicious findings in con-
nection with the preceding examination or CT scan.
Twenty-two patients (22%) relapsed after a median time of
5 months (range 2-18), the median observation time being
47 months for recurrence-free patients. Invasion of small
blood or lymphatic vessels was the most significant risk
factor predicting relapse (P = 0.007). The retroperitoneal
space was the most frequent site of recurrence (14 patients,
Table I). The median size of the retroperitoneal recurrence
was 25 mm (range 13-60 mm). Four patients had lung
metastases, in three patients these were visible only on CT
scans. Fourteen patients relapsed without marker increase,
and four had isolated raised APP and/or HCG without
detectable tumour manifestations. Patients with normal
preorchiectomy serum tumour markers had a minimal chance
(1 of 13) of presenting with AFP/HCG elevation at the time
of recurrence (Table II). Even among 18 relapsing patients
with elevated preorchiectomy levels only seven presented with
elevated AFP/HCG values at the time of recurrence.
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Figure 1 Number of follow-up examinations in 80 recurrence-
free patients with stage I low-risk non-seminomatous testicular
cancer on surveillance. a, Number of clinical follow-up examina-
tions. b, Number of abdominal/thoracic CT scans.1158 S.D. FOSSA et al.
Table I Examinations indicating the relapse in 22 patients
No of Abdominal Thoracic Chest Clinical
patients AFP/HCG CT CT radiograph examination
9 -a +-b
4 + + - _ _
4 + _ _ _ _
2 - - + _ _
1 - + + _ _
1 - - + + _
IC - - - +
No of patients
with pathological
findings 8 14 4 1 1
aNormal. bElevated. 3 cm large scroto-inguinal recurrence, also visible on pelvic CT
(normal abdominal CT).
Table II Tumour marker levels at relapse in patients with known
pre-orchiectomy AFP/HCG
At relapse
Pre-orchiectomy Normal Elevated Total
AFP
Normal 4 0 4
Elevated 8 4 12
Total 12 4 16
HCG
Normal 8 1 9
Elevated 3 3 6
Total 11 4 15
All relapsing patients received cisplatin- or carboplatin-
based chemotherapy, eventually followed by RLND. All but
one patient, who presented with rhabdomyosarcomatous
elements in his primary tumour, were salvaged. The
progression-free and cancer-specific 5 year survival was 78%
and 99% respectively.
For about 50% of the evaluable patients the surveillance
programme had been easy or very easy, whereas 50% of the
patients recorded that during the follow-up period they had
been mildly or moderately distressed, which they attributed
to the management of their malignancy (Table III).
Discussion
The overall outcome in non-seminoma stage I patients
managed by this surveillance policy is similar to that of a
programme using primary RLND achieving survival percen-
tages in the range of 98-100%. Limited other experience
about the practical limitations and real-life problems
encountered during the surveillance programmes has been
reported. Pizocarro et al. (1986), Moul et al. (1990) and
Young et al. (1991) have, however, emphasised that the
surveillance policy may be problematic as some patients are
not completely compliant.
In 1987 we were aware of an approximately 30-50% risk
of recurrence in patients with high-risk factors (Freedman et
al., 1987; Aass et al., 1990). High-risk patients were a priori
considered to be ineligible for surveillance owing to lack of
sufficient CT resources and in view of Norway's geography.
(The largest diameter in the country's south-north direction
is 1,600 km.) Only histologically low-risk patients were
included in our surveillance policy and a relapse rate of
15-20% was expected. Patients with clinical stage I could,
after receiving detailed information, choose whether they
preferred surveillance or nerve-sparing RLND, this operation
being successfully introduced at our hospital in 1987. All
patients selected surveillance. It is thus the physician's res-
ponsibility to discriminate in advance between those patients
in whom wait and see is possible from those in whom this
Table III Psychological and physical parameters in 68
recurrence-free patients after 1 year surveillance and 46 similar
patients after 3 years
No. of patients
1 year 2 years
Satisfaction with own situation
Very satisfied/satisfied
Somewhat satisfied/mixed/
somewhat dissatisfied
Feeling of strength and energy
Very strong and energetic/
strong and energetic
Somewhat strong and energetic/mixed/
somewhat tired and run down
Tired and run down/
very tired and run down
Evaluation of treatment period
Very easy/easy
Somewhat easy/mixed/
somewhat problematic
33 (49)
35 (51)
0
25
20
1
23 (34) 14
40 (59) 30
5 (7) 2
(54)
(43)
(2)
(30)
(65)
(4)
31 (53) 21b (53)
21 (36) 14 (35)
Problematic/very problematic 6 (10) 5 (11)
as8 evaluable patients. b40 evaluable patients.
policy is not feasible and to whom it should not be offered.
Most often the physician's overall clinical judgement of the
individual case will determine whether or not surveillance can
be offered to a patient. Despite of these rather 'soft' criteria,
our study shows that the reasonably safe selection of patients
suitable for wait and see is possible. Only 1 of 102 patients
refused to adhere to the, scheduled controls during the first
post-orchiectomy year. The surveillance policy, however,
places a great responsibility on the caring physicians and on
the cancer hospital to offer a safe surveillance programme.
Patients who do not attend a scheduled follow-up visit
should be traced immediately and reminded to come to the
control visits. Following these rules non-compliance during
the first year of follow-up has not been a major problem in
our experience, as for example described by Young et al.
(1991) and by Moul et al. (1990).
Cooperation between the oncological centre and the local
hospitals' oncologists/urologists and radiologists is essential.
At the consensus meeting at the start of the surveillance
programme radiologists from the local hospitals were in-
formed about the time schedule and optimal technique and
given the appropriate description of the necessary CT scans.
However, about 30% of the reviewed CT scans from local
hospitals revealed some technical errors or misinterpretations
which would have led to inadequate treatment in 5% of the
examined patients (Fossa et al., 1993). In cases with doubtful
results the responsible oncological centre must therefore have
the resources to perform necessary supplementary examina-
tions (blood tests, clinical examinations, CT scan, ultrasonog-
raphy) without longer delay even though this may mean
repeated CT examinations at short intervals. If these condi-
tions of cooperation and immediate availability of controlSURVEILLANCE IN LOW-RISK TESTICULAR NON-SEMINOMA 1159
tests are not fulfilled, the surveillance policy is in our view
ethically and medically indefensible.
Real-life experience from our institution shows that the
above requirements occasionally can be met only with
difficulties, i.e. during holidays, breakdown of CT machines,
extraordinary workload on the medical staff, etc. Such
administrative problems are the main reasons why 27 of our
80 recurrence-free patients had fewer than the four recom-
mended CT scans during the first year, and 23 patients had
fewer than ten follow-up visits.
Most patients relapse retroperitoneally. The diagnosis of
retroperitoneal recurrence may be difficult even for an
experienced radiologist at an oncological centre. In two of
our patients with normal serum tumour markers the ret-
roperitoneal masses were not diagnosed or misinterpreted on
CT scans taken at the NRH respectively 2 and 8 months
before the definite diagnosis of relapse. The surveillance
policy requires a high level of experience of not only the
oncologist/urologist but of all the members of the medical
staff. In agreement with the view of Pizzocaro et al. (1986),
the surveillance policy should only be introduced at hospitals
were a sufficient number of patients are seen to gain this
knowledge. For testicular cancer patients in general, Harding
et al. (1993) have pointed out that larger units obtain better
results than the small units. Our group has reported similar
observations in patients receiving chemotherapy ± surgery
for metastatic cancer (Aass et al., 1991). Seemingly
unavoidable technical errors and misinterpretations of CT
scans, most often occurring at local hospitals (Fossa et al.,
1993), may be one reason for a more favourable survival seen
at a larger cancer centre.
Nerve-sparing RLND (Jewett et al., 1988; Donohue et al.,
1993) is a reasonable alternative to surveillance and does not
usually lead to long-lasting sequelae. The operation
represents, however, major surgery with 6-8 weeks' sick
leave in most patients. It is a purely diagnostic procedure in
80-95% of low-risk patients with non-seminomatous stage I
cancer. About 10-20% of patients with surgical stage I will
develop lung metastases during follow-up (Klepp et al.,
1991). Although the frequency of follow-up visits can be
reduced after RLND, and multiple routine abdominal CT
scans probably are not necessary, the patients still have to
attend to control visits relatively often (every second month
during the first 12-18 months). The overall advantage of
RLND is therefore debatable as compared with the wait and
see policy, provided that surveillance routines are safe and
there is adequate selection of patients.
It is sometimes claimed that the surveillance policy
represents a highly distressing situation for the patients and
that primary RLND would be preferable for most of them.
Our experience does not support this suggestion. Most
patients were satisfied and felt safe with the surveillance
programme despite the high frequency of follow-up visits,
often necessitating long-distance travel. Admittedly, one ex-
planation of the psychological satisfaction in our patients
may be that Norwegian testicular cancer patients usually feel
very confident with the treatment recommendations made by
the NRH, which is the country's oldest and largest cancer
hospital.
Conclusion
Even in a geographically large country a surveillance pro-
gramme is safe in compliant low-risk patients with clinical
stage I non-seminomatous testicular cancer. The policy
requires an excellent cooperation with other institutions,
which should have experience with CT scanning in this type
of patient.
An institution which recommends surveillance has an
obligation to monitor the individual patient's management
and to ensure that the necessary resources for satisfactory
follow-up are available.
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